Pharmacokinetic Drug–Drug Interactions of DA-8010 with Clarithromycin or Rifampicin: Influence of CYP2D6 Phenotype on the Extent of These Interactions

Le résumé fourni par la source

Purpose: This study aimed to evaluate the pharmacokinetic (PK) drug-drug interactions (DDIs) of DA-8010 with clarithromycin or rifampicin, and to assess the influence of cytochrome P450 (CYP) 2D6 phenotype on the extent of these interactions. Methods: An open-label, fixed-sequence, three-period crossover study was conducted in healthy participants. Participants received a single dose of DA-8010 5 mg alone on Day 1 (Period 1); clarithromycin 500 mg twice daily from Day 6 to 11, with a concomitant single dose of DA-8010 5 mg on Day 10 (Period 2); and rifampicin 600 mg once daily from Day 16 to 25, with a concomitant single dose of DA-8010 5 mg on Day 25 (Period 3). Each treatment period was separated by a five-day washout. Serial blood samples for PK assessments of DA-8010 were collected up to 48 h post-dose. CYP2D6 genotyping was performed retrospectively, and phenotypes were assigned based on activity score. Results: Sixteen participants completed the study: eleven were classified as CYP2D6 extensive metabolizers (EMs) and five as CYP2D6 intermediate metabolizers (IMs). Co-administration of DA-8010 with clarithromycin had no significant effect on the PKs of DA-8010. In contrast, co-administration with rifampicin reduced the systemic exposure of DA-8010 by approximately 50% compared with DA-8010 alone. Across all treatment conditions, DA-8010 exposure was approximately two-fold higher in IMs than in EMs. Conclusion: DA-8010 showed no clinically meaningful PK interaction with clarithromycin, while rifampicin significantly reduced DA-8010 exposure. Although the CYP2D6 phenotype affected overall DA-8010 exposure, it did not alter the extent of the PK interaction observed with clarithromycin or rifampicin.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.